CLDX vs CV: fair value comparison
Celldex Therapeutics, Inc. and CapsoVision, Inc. · Updated 2026-10-19
CLDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CV has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CLDX currently ranks higher by quality score.
| CLDX | CV | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $27.53 | $6.53 |
| 12-month range | $22.58–$44.87 | $4.59–$14.42 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #182 of 301 Healthcare | #184 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: CLDX fair value analysis · CV fair value analysis